A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Inclusion Criteria:
- Histologically confirmed locally advanced or metastatic thyroid
cancer - Measurable disease - Normal blood pressure (if history of hypertension, blood
pressure must be controlled with medication) - Evidence of disease progression within 6
months before starting study (for differentiated thyroid cancer subjects) - Evidence of
disease progression within 6 months before starting study OR symptomatic disease (for
medullary thyroid cancer subjects) - Not a candidate for surgical resection, external beam
radiotherapy, radioiodine therapy, or other local therapy - At least 18 years of age
Exclusion Criteria: - Undifferentiated/anaplastic thyroid cancer - Untreated or
symptomatic brain metastases - Prior malignancy, unless cured with treatment and no
evidence of disease for greater than or equal to 3 years before starting study (history of
thyroid cancer, in situ cervical cancer, or basal cell cancer of skin are exceptions) -
Myocardial infarction or any unstable cardiac condition (e.g., congestive heart failure,
unstable angina) within 1 year before starting study - Arterial thrombosis or deep vein
thrombosis within 1 year before starting study